|Bid||53.25 x 1100|
|Ask||53.30 x 4000|
|Day's Range||52.62 - 53.53|
|52 Week Range||36.15 - 64.94|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||56.05|
|Forward Dividend & Yield||1.40 (2.66%)|
|Ex-Dividend Date||Aug. 13, 2020|
|1y Target Est||62.35|
Yahoo Finance’s Alexis Christoforous and Eric Mosley, the CEO of Workhuman, discuss how his company is helping employers address mental health amid the pandemic.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN) to AstraZeneca PLC (NasdaqGS: AZN). Under the terms of the proposed transaction, shareholders of Alexion will receive only $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca for each share of Alexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
AstraZeneca said initial deliveries to the European Union of the COVID-19 vaccine it is developing with Oxford University will fall short of the targeted volumes because of a glitch in production. "We will be supplying tens of millions of doses in February and March to the European Union, as we continue to ramp up production volumes," he added.